Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

About this update from Aurinia Pharmaceuticals Inc

ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024 , before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free U.S. & Canada ). The audio webcast can also be accessed here . A replay of the webcast will be available on Aurinia’s website. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021 , the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta , its U.S. commercial office is in Rockville, Maryland . The Company focuses its development efforts globally. View source version on businesswire.com : https://www.businesswire.com/news/home/20240719692619/en/ Media and Investor Inquiries: Andrea Christopher Corporate Communications and Investor Relations, Aurinia [email protected] [email protected] Source: Aurinia Pharmaceuticals Inc.

View stock analysis, news, and events for Aurinia Pharmaceuticals Inc